Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Joins Forces with Nobel Laureate to Tackle AMR Infections
October 25, 2017
- Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
October 25, 2017
- Mitsubishi Tanabe Trims Forecast on Sluggish Invokana Royalties
October 25, 2017
- BMS, Pfizer Launch Japan Clinical Research for Atrial Fibrillation Detection
October 24, 2017
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed
October 24, 2017
- Shionogi Ups Earnings Outlook on Milestone Scheme Change
October 24, 2017
- AZ’s Olaparib Filed for Breast Cancer in 2nd Submission
October 24, 2017
- Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030
October 24, 2017
- Harvoni Hits 96% SVR12 Rate in Japanese Genotype 2 Hep C Patients
October 23, 2017
- Romosozumab Shows Consistent Efficacy, Safety in Japanese Osteoporosis Patients: Amgen Astellas
October 23, 2017
- Astellas Inks Collaboration with Universal Cells to Develop Novel Cell Therapy
October 23, 2017
- Seebri Neohaler Now Available in the US: Sunovion
October 23, 2017
- Lonsurf Earns Priority Status in Canada: Taiho
October 23, 2017
- Topical Sirolimus, 1st Sakigake-Designated Drug, Filed in Japan: Nobelpharma
October 23, 2017
- Kaketsuken Mum on Reported Biz Transfer to Kumamoto Consortium-Led Firm
October 20, 2017
- Mitsubishi Tanabe’s NeuroDerm Acquisition Completed
October 20, 2017
- LEO Pharma Japan to Set Up Stand-Alone Sales Force in 5 Years, Eyes 100 Reps
October 20, 2017
- Takeda’s Entrepreneurship Scheme Attracts 30 Proposals
October 20, 2017
- Boehringer, Nagoya City Univ. Collaborate on Diabetic Retinopathy Research
October 19, 2017
- Astellas, US Nonprofit Join Forces to Discover TB Drugs
October 19, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…